New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 113.6mg equivalent to lanreotide 90 mg - solution for injection - 90 mg - active: lanreotide acetate 113.6mg equivalent to lanreotide 90 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - lanreotide acetate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 16 iu - diluent, not applicable - excipient ingredients: metacresol; water for injections - short stature due to decreased or failed secretion of pituitary growth hormone. indications as at 20 march 2001: short stature due to decreased or failed secretion of pituitary hormone. growth distrubances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 26 november 2001: short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanograms/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. indications as at 13 june 2003: short stature due to decreased or failed secretion of pituit

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - somatropin, quantity: 5.3 mg/ml - injection, powder for - excipient ingredients: glycine; mannitol; monobasic sodium phosphate; dibasic sodium phosphate - short stature due to decreased or failed secretion of pituitary growth hormone. treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. growth disturbances associated with gonadal dysgenesis (turner's syndrome). improvement of body composition and treatment of short stature associated with prader-willi syndrome (pws) in paediatric patients. for treatment of growth disturbance in children with chronic renal insufficiency whose height is on or less than twenty-fifth percentile and whose growth velocity is on or less than twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 50 ml/min/1.73m2.

USA - engelsk - NLM (National Library of Medicine)

ipsen biopharmaceuticals, inc. - lanreotide acetate (unii: ieu56g3j9c) (lanreotide - unii:0g3de8943y) - lanreotide 60 mg in 0.2 ml - somatuline depot is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. the goal of treatment in acromegaly is to reduce growth hormone (gh) and insulin growth factor-1 (igf-1) levels to normal. somatuline depot is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (gep-nets) to improve progression-free survival. somatuline depot is indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. somatuline depot is contraindicated in patients with history of a hypersensitivity to lanreotide. allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide [ see adverse reactions (6.3)] . risk summary limited available

USA - engelsk - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 5 mg in 1 ml - genotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. genotropin is indicated for the treatment of pediatric patients who have growth failure due to prader-willi syndrome (pws). the diagnosis of pws should be confirmed by appropriate genetic testing [see contraindications (4)] . genotropin is indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to manifest catch-up growth by age 2 years. genotropin is indicated for the treatment of growth failure associated with turner syndrome. genotropin is indicated for the treatment of idiopathic short stature (iss), also called non-growth hormone-deficient short stature, defined by height standard deviation score (sds) ≤-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other c

USA - engelsk - NLM (National Library of Medicine)

genentech, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 10 mg in 2 ml - growth hormone deficiency (ghd) - nutropin aq® is indicated for the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous growth hormone (gh). growth failure secondary to chronic kidney disease (ckd) - nutropin aq is indicated for the treatment of growth failure associated with ckd up to the time of renal transplantation. nutropin aq therapy should be used in conjunction with optimal management of ckd. idiopathic short stature (iss) - nutropin aq is indicated for the treatment of iss, also called non-ghd short stature, defined by height sds ≤ –2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means. short stature associated with turner syndrome (ts) - nutropin aq is indicated for the treatment of short stature associated wit

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - somatropin, quantity: 6 mg (equivalent: somatropin, qty 18 iu) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; glycerol; hydrochloric acid; metacresol - humatrope is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,humatrope is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (turner syndrome).,humatrope is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. in patients with childhood onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low igf-i concentrations less than or equal to 2 sds who may be considered for one test. the cut-off point of the dynamic test should be strict.,humatrope is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2.,humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years (see clinical trials). humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years. (see clinical trials)

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - somatropin, quantity: 12 mg (equivalent: somatropin, qty 36 iu) - injection, solution - excipient ingredients: hydrochloric acid; metacresol; sodium hydroxide; glycerol; water for injections - humatrope is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,humatrope is also indicated for the treatment of growth disturbances associated with gonadal dysgenesis (turner syndrome).,humatrope is also indicated for the treatment of adults with severe growth hormone deficiency defined as patients with known hypothalamic-pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a growth deficiency. in patients with childhood onset isolated gh deficiency (no evidence of hypothalamic-pituitary disease or cranal irradiation), two dynamic tests should be recommended, except for those having low igf-i concentrations less than or equal to 2 sds who may be considered for one test. the cut-off point of the dynamic test should be strict.,humatrope is also indicated for the treatment of growth retardation in prepubertal children with chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2.,humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years (see clinical trials). humatrope is also indicated for the treatment of growth failure in children born small for gestational age (sga) who fail to demonstrate catch-up growth by age two to four years. (see clinical trials)